Lunai Bioworks (NASDAQ:LNAI) Releases Quarterly Earnings Results

Lunai Bioworks (NASDAQ:LNAI) posted its quarterly earnings data on Tuesday. The company reported ($0.08) earnings per share for the quarter, Zacks reports.

Lunai Bioworks Trading Down 8.8%

NASDAQ LNAI traded down $0.06 during trading on Tuesday, hitting $0.67. The company’s stock had a trading volume of 417,612 shares, compared to its average volume of 249,696. Lunai Bioworks has a fifty-two week low of $0.63 and a fifty-two week high of $14.00. The company has a market capitalization of $15.70 million, a P/E ratio of -9.57 and a beta of 0.46. The firm’s 50 day moving average is $0.91.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lunai Bioworks stock. Millennium Management LLC acquired a new position in shares of Lunai Bioworks Inc. (NASDAQ:LNAI) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned 0.87% of Lunai Bioworks as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 71.41% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Lunai Bioworks in a report on Monday, December 29th. Wall Street Zen raised Lunai Bioworks from a “sell” rating to a “hold” rating in a research note on Saturday, January 10th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Lunai Bioworks has an average rating of “Sell”.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.